- Home
- TALK vs KALV Comparison
TALK vs KALV Comparison
Compare TALK & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALK
- KALV
- Stock Information
- Founded
- TALK 2012
- KALV N/A
- Country
- TALK United States
- KALV United States
- Employees
- TALK N/A
- KALV N/A
- Industry
- TALK Medical/Nursing Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- TALK Health Care
- KALV Health Care
- Exchange
- TALK Nasdaq
- KALV Nasdaq
- Market Cap
- TALK 480.0M
- KALV 563.1M
- IPO Year
- TALK N/A
- KALV N/A
- Fundamental
- Price
- TALK $2.58
- KALV $11.41
- Analyst Decision
- TALK Buy
- KALV Strong Buy
- Analyst Count
- TALK 5
- KALV 8
- Target Price
- TALK $4.38
- KALV $24.83
- AVG Volume (30 Days)
- TALK 2.0M
- KALV 619.3K
- Earning Date
- TALK 05-06-2025
- KALV 03-12-2025
- Dividend Yield
- TALK N/A
- KALV N/A
- EPS Growth
- TALK N/A
- KALV N/A
- EPS
- TALK 0.01
- KALV N/A
- Revenue
- TALK $187,593,000.00
- KALV N/A
- Revenue This Year
- TALK $23.45
- KALV N/A
- Revenue Next Year
- TALK $21.15
- KALV N/A
- P/E Ratio
- TALK $385.88
- KALV N/A
- Revenue Growth
- TALK 25.02
- KALV N/A
- 52 Week Low
- TALK $1.60
- KALV $7.30
- 52 Week High
- TALK $4.36
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- TALK 35.64
- KALV 47.44
- Support Level
- TALK $2.71
- KALV $11.83
- Resistance Level
- TALK $2.96
- KALV $12.50
- Average True Range (ATR)
- TALK 0.12
- KALV 0.58
- MACD
- TALK -0.00
- KALV -0.16
- Stochastic Oscillator
- TALK 19.79
- KALV 19.46
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.